Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 5:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 61 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Treatment Resistant Depression (TRD) Clear all
Not yet recruiting Phase 1 Interventional

Ketamine Biomarker Validation

NCT07307768
View directory record Official record
Conditions
Treatment Resistant Depression (TRD)
Interventions
Ketamine (0.25 mg/kg), Ketamine (0.5 mg/kg), Ketamine (0.75 mg/kg)
Drug
Lead sponsor
Soterix Medical
Industry
Eligibility
18 Years to 59 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Sep 25, 2026, 5:32 PM EDT
Recruiting Phase 2 Interventional

Intravenous Ketamine for Treatment-Resistant Depression

NCT06668571
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
Interventions
Ketamine, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 25, 2026, 5:32 PM EDT
Recruiting Not applicable Interventional

Magnetic Seizure Therapy in Bipolar Depression (MST-BpD) and Treatment Resistant Depression (MST-TRD)

NCT04080778
View directory record Official record
Conditions
Bipolar Disorder
Interventions
magnetic seizure therapy (MST), electroconvulsive therapy (ECT)
Device
Lead sponsor
Joao L. DeQuevedo
Other
Eligibility
22 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 25, 2026, 5:32 PM EDT
Recruiting Not applicable Interventional

taVNS or TMS or Both for Depression

NCT05725239
View directory record Official record
Conditions
Depression
Interventions
Vagus Nerve Stimulation, Transcranial Magnetic Stimulation
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 25, 2026, 5:32 PM EDT
Recruiting Not applicable Interventional

Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression: A Home-Based Feasibility and Safety Study

NCT07217223
View directory record Official record
Conditions
Treatment Resistant Depression (TRD), Major Depressive Disorder (MDD)
Interventions
Spaced Transcranial Direct Current Stimulation (tDCS)
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 25, 2026, 5:32 PM EDT
Completed No phase listed Observational

Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)

NCT04519957
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Not listed
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Timeline
2020 – 2022
U.S. locations
4
States / cities
La Jolla, California • San Diego, California • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Sep 25, 2026, 5:32 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

NCT01369095
View directory record Official record
Conditions
Depression
Interventions
Duloxetine, Escitalopram, BMS-820836 Placebo, BMS-820836
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
48
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Chino, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 25, 2026, 5:32 PM EDT
Active, not recruiting Phase 3 Interventional

Psilocybin-Assisted Therapy in Treatment-Resistant Depression

NCT06303739
View directory record Official record
Conditions
Refractory Depression, Treatment Resistant Depression
Interventions
psilocybin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 25, 2026, 5:32 PM EDT
Recruiting Not applicable Interventional

DBS for TRD With the Medtronic Percept PC

NCT05773755
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
Medtronic Percept PC DBS system
Device
Lead sponsor
Helen Mayberg, MD
Other
Eligibility
25 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 25, 2026, 5:32 PM EDT
Completed Phase 2Phase 3 Interventional Results available

ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)

NCT03113968
View directory record Official record
Conditions
Treatment Resistant Depression, Electroconvulsive Therapy, ECT, Ketamine, Psychiatric Disorder, Depression, Major Depressive Disorder, Major Depressive Episode, Unipolar Depression
Interventions
electroconvulsive therapy (ECT), Ketamine
Procedure · Drug
Lead sponsor
Bo Hu
Other
Eligibility
21 Years to 75 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
5
States / cities
New Haven, Connecticut • Baltimore, Maryland • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 25, 2026, 5:32 PM EDT
Completed Phase 3 Interventional

A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder

NCT02741791
View directory record Official record
Conditions
Treatment Resistant Major Depressive Disorder
Interventions
AXS-05, Bupropion
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
74
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 71 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 25, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)

NCT05454410
View directory record Official record
Conditions
Treatment-Resistant Depression
Interventions
MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg, Placebo Subcutaneous Injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
3
States / cities
Birmingham, Alabama • Oakland Park, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Sep 25, 2026, 5:32 PM EDT
Completed Not applicable Interventional

Exercise in Treatment Resistant Depression (TRD): A Feasibility Study

NCT01383811
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Moderate Intensity Aerobic Exercise, Wait-list
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Sep 25, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD

NCT05414422
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
PCN-101, Placebo
Drug
Lead sponsor
Perception Neuroscience
Industry
Eligibility
18 Years to 65 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
13
States / cities
Little Rock, Arkansas • Garden Grove, California • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 25, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

Optimization of IV Ketamine for Treatment Resistant Depression

NCT00768430
View directory record Official record
Conditions
Major Depressive Disorder (MDD), Treatment Resistant Depression (TRD)
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Sep 25, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)

NCT01920555
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Ketamine, Placebo Midazolam
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Palo Alto, California • New Haven, Connecticut • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Sep 25, 2026, 5:32 PM EDT
Completed Phase 4 Interventional Results available

Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD

NCT02977299
View directory record Official record
Conditions
Treatment Resistant Major Depressive Disorder
Interventions
Aripiprazole, Repetitive transcranial magnetic stimulation (rTMS), Venlafaxine XR
Drug · Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 25, 2026, 5:32 PM EDT
Completed Phase 3 Interventional

Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

NCT05624268
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
40
States / cities
Tuscon, Arizona • Culver City, California • Garden Grove, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 25, 2026, 5:32 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)

NCT04663321
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
MK-1942, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
45
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bellflower, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 25, 2026, 5:32 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial

NCT07227103
View directory record Official record
Conditions
Treatment Resistant Depression, Treatment Resistant Depression (TRD)
Interventions
Neuronavigated robotic-enabled TMS, NRX-101, Sham TMS, Oral Placebo
Device · Drug
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Sarasota, Florida • West Palm Beach, Florida • Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 25, 2026, 5:32 PM EDT
Active, not recruiting Not applicable Interventional

DBS of the Lateral Habenula in Treatment-Resistant Depression

NCT01798407
View directory record Official record
Conditions
Treatment Resistant Major Depressive Disorder
Interventions
Activa Tremor Control Sys (DBS Implant), Randomized, staggered withdrawal phase
Device · Other
Lead sponsor
Wayne Goodman MD
Other
Eligibility
21 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2025 · Synced Sep 25, 2026, 5:32 PM EDT
Terminated Early Phase 1 Interventional Results available

Nitrous TRD Bipolar Depression

NCT02757521
View directory record Official record
Conditions
Treatment- Resistant Bipolar Disorder, Bipolar Disorder, Bipolar Depressive Disorder
Interventions
Nitrous Oxide, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Sep 25, 2026, 5:32 PM EDT
Active, not recruiting Not applicable Interventional

Transcranial Direct Current Stimulation (tDCS) as an Adjunctive Treatment for Treatment Resistant Depression (TRD)

NCT06236711
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
tDCS
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 25, 2026, 5:32 PM EDT
Completed Not applicable Interventional Results available

Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression (SAINT-TRD)

NCT03068715
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Active TBS-DLPFC, Sham TBS-DLPFC, Open label TBS-DLPFC
Device
Lead sponsor
Stanford University
Other
Eligibility
22 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Sep 25, 2026, 5:32 PM EDT